Quantcast

Latest CSL Behring Stories

2014-07-30 12:30:36

Findings presented at the 2014 World Transplant Congress SAN FRANCISCO, July 30, 2014 /PRNewswire/ -- A study presented at the 2014 World Transplant Congress evaluated the safety and efficacy of CSL Behring's C1 Inhibitor (C1-INH) concentrate in preventing antibody-mediated rejection following kidney transplants in highly sensitized patients. C1-INH is a human protein and an important inhibitor of the complement system. http://photos.prnewswire.com/prnvar/20100914/PH63692LOGO The...

2014-07-21 16:26:21

DUBLIN, July 21, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/hjmbvk/latestage) has announced the addition of the "Late-Stage Four-FCritical Care Therapeutics in Major Developed Markets to 2020 - New andactor PCCs and Recombinant Products to Drive Market" [http://www.researchandmarkets.com/research/hjmbvk/latestage ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This report provides...

2014-06-24 08:32:22

Interlaken Leadership Awards Program Supports Original Research in the Field of Neuroimmunology KING OF PRUSSIA, Pa., June 24, 2014 /PRNewswire/ -- CSL Behring announced today that Bart C. Jacobs, M.D., Ph.D., Erasmus University Medical Center, Rotterdam, Netherlands, is the recipient of the 2014 Interlaken Leadership Awards for original research in the field of neuroimmunology. Established in 2010, this annual global awards program provides monetary grants and/or product supply for...

2014-05-28 23:16:22

Pharmica Consulting, the industry leader in life science processes and technology, is pleased to announce that Dr. Eric Towler of CSL Behring will speak at Pharmica’s Portfolio and Resource Management Conference on October 14th and 15th in Philadelphia, PA. Philadelphia, PA (PRWEB) May 28, 2014 As part of its continued service to the industry, Pharmica will host its Portfolio and Resource Management Conference in Philadelphia, PA on October 14-15, 2014. The two-day conference will...

2014-05-20 08:34:27

Eligible Participants to Receive Payment Assistance with Out-of-Pocket Costs Associated with Hizentra® Therapy in the United States KING OF PRUSSIA, Pa., May 20, 2014 /PRNewswire/ -- People managing primary immunodeficiency (PI) with CSL Behring's Hizentra(®) (Immune Globulin Subcutaneous [Human]) may now be eligible for financial support through the Hizentra(®) Co-Pay Relief Program. The new program offers eligible U.S. patients up to $4,000 per year to be applied toward Hizentra...

2014-05-14 08:31:29

Third annual awareness day shines a light on rare, potentially life-threatening condition KING OF PRUSSIA, Pa., May 14, 2014 /PRNewswire/ -- As a Diamond Sponsor of HAE Day on May 16, 2014, CSL Behring is proud to continue its partnership with HAEi, the International Patient Organization for C1 Inhibitor Deficiencies, and patient organizations throughout the world. HAE, or, hereditary angioedema, is a rare, potentially fatal swelling disorder caused by a deficiency of C1-INH, a type of...

2014-05-11 20:21:16

Data showing improved pharmacokinetic profile to be presented at World Federation of Hemophilia Congress MELBOURNE, Australia, May 11, 2014 /PRNewswire/ -- Interim Phase II/III and III findings presented today by CSL Behring at the World Federation of Hemophilia (WFH) 2014 Congress demonstrate an improved pharmacokinetic (PK) profile of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) among hemophilia B patients of all age groups. These...

2014-05-09 12:25:57

-- Leading-edge science at the core of $250 million expansion to drive long-term growth in promising bleeding disorders portfolio KING OF PRUSSIA, Pa., May 9, 2014 /PRNewswire/ -- CSL Limited (ASX:CSL), parent company of CSL Behring which is based in King of Prussia, PA, today opened the CSL Behring Biotechnology Manufacturing Facility in Melbourne, Australia. The new facility, located adjacent to the site's manufacturing plant for plasma products, is the centerpiece of CSL's...

2014-05-05 20:26:32

LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024http://www.reportbuyer.com/pharma_healthcare/diseases/bleeding_disorders_world_pharmaceutical_industry_market_2014_2024.htmlReport DetailsTreating abnormal bleeding - this new report shows you trends, R&D outlooks, and sales forecastsTreatments for bleeding - what're their prospects? Visiongain's new report gives you...

2014-05-02 08:25:41

KING OF PRUSSIA, Pa., May 2, 2014 /PRNewswire/ -- CSL Behring today announced that the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the efficacy, safety and pharmacokinetics of its novel investigational recombinant factor VIII single chain (rVIII-SingleChain) for the treatment of previously treated children (up to age 11 years) with severe hemophilia A. The study site for this first enrollment is Malaysia. A minimum of 25 previously treated...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related